Last reviewed · How we verify

VXA-A1.1 Oral Vaccine

Vaxart · Phase 1 active Biologic Quality 3/100

VXA-A1.1 Oral Vaccine is a Biologic drug developed by Vaxart. It is currently in Phase 1 development. Also known as: Ad-HA-dsRNA (VXA-A1.1).

At a glance

Generic nameVXA-A1.1 Oral Vaccine
Also known asAd-HA-dsRNA (VXA-A1.1)
SponsorVaxart
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about VXA-A1.1 Oral Vaccine

What is VXA-A1.1 Oral Vaccine?

VXA-A1.1 Oral Vaccine is a Biologic drug developed by Vaxart.

Who makes VXA-A1.1 Oral Vaccine?

VXA-A1.1 Oral Vaccine is developed by Vaxart (see full Vaxart pipeline at /company/vaxart).

Is VXA-A1.1 Oral Vaccine also known as anything else?

VXA-A1.1 Oral Vaccine is also known as Ad-HA-dsRNA (VXA-A1.1).

What development phase is VXA-A1.1 Oral Vaccine in?

VXA-A1.1 Oral Vaccine is in Phase 1.

What are the side effects of VXA-A1.1 Oral Vaccine?

Common side effects of VXA-A1.1 Oral Vaccine include Upper Respiratory Infection, Headache.

Related